Cargando…
The use of methylphenidate in vascular dementia: A case report
INTRODUCTION: Patients diagnosed with vascular dementia often present with apathy, executive dysfunction or/and memory impairment. Some of these psychiatric domains are not responsive to antidepressants or acetylcholinesterase inhibitors. Since methylphenidate enhances frontal lobe function, it may...
Autores principales: | , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cambridge University Press
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475915/ http://dx.doi.org/10.1192/j.eurpsy.2021.1136 |
_version_ | 1784790021120720896 |
---|---|
author | Regueira, P. Cerejeira, J. |
author_facet | Regueira, P. Cerejeira, J. |
author_sort | Regueira, P. |
collection | PubMed |
description | INTRODUCTION: Patients diagnosed with vascular dementia often present with apathy, executive dysfunction or/and memory impairment. Some of these psychiatric domains are not responsive to antidepressants or acetylcholinesterase inhibitors. Since methylphenidate enhances frontal lobe function, it may be a valid therapeutic option. OBJECTIVES: To report a case where methylphenidate was used as a therapeutic approach in vascular dementia. METHODS: We present a case of a patient diagnosed with vascular dementia with substantial clinical improvement after treatment with methylphenidate. RESULTS: A 67 year-old male was observed in a psychiatric consultation reporting memory loss, inability to retain information and inattention. According to her spouse, the patient has been mostly isolated at home and recently he has become unable to accomplish some daily living activities. There was no history of previous psychiatric disorder. Cognitive assessment was performed using MoCA test: 19/30 points (predominantly in executive, attention and delayed recall domains). After this evaluation, it was introduced bupropion 150mg od and donepezil 5mg od with insignificant clinical improvement. The patient underwent a routine workup which was unremarkable and a brain computed tomography scan that revealed ischemic leukoencephalopathy. Three months later no clinical benefit was reported. Attention and functional improvement were observed after introduction of methylphenidate with progressive dose adjusting till 30 mg/day. CONCLUSIONS: Besides not being a consensual therapeutic approach, considering that there is a lack of efficient pharmacological strategies in vascular dementia, methylphenidate may play a significant role in this field contributing to clinical improving and ultimately to an enhanced quality of life. |
format | Online Article Text |
id | pubmed-9475915 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Cambridge University Press |
record_format | MEDLINE/PubMed |
spelling | pubmed-94759152022-09-29 The use of methylphenidate in vascular dementia: A case report Regueira, P. Cerejeira, J. Eur Psychiatry Abstract INTRODUCTION: Patients diagnosed with vascular dementia often present with apathy, executive dysfunction or/and memory impairment. Some of these psychiatric domains are not responsive to antidepressants or acetylcholinesterase inhibitors. Since methylphenidate enhances frontal lobe function, it may be a valid therapeutic option. OBJECTIVES: To report a case where methylphenidate was used as a therapeutic approach in vascular dementia. METHODS: We present a case of a patient diagnosed with vascular dementia with substantial clinical improvement after treatment with methylphenidate. RESULTS: A 67 year-old male was observed in a psychiatric consultation reporting memory loss, inability to retain information and inattention. According to her spouse, the patient has been mostly isolated at home and recently he has become unable to accomplish some daily living activities. There was no history of previous psychiatric disorder. Cognitive assessment was performed using MoCA test: 19/30 points (predominantly in executive, attention and delayed recall domains). After this evaluation, it was introduced bupropion 150mg od and donepezil 5mg od with insignificant clinical improvement. The patient underwent a routine workup which was unremarkable and a brain computed tomography scan that revealed ischemic leukoencephalopathy. Three months later no clinical benefit was reported. Attention and functional improvement were observed after introduction of methylphenidate with progressive dose adjusting till 30 mg/day. CONCLUSIONS: Besides not being a consensual therapeutic approach, considering that there is a lack of efficient pharmacological strategies in vascular dementia, methylphenidate may play a significant role in this field contributing to clinical improving and ultimately to an enhanced quality of life. Cambridge University Press 2021-08-13 /pmc/articles/PMC9475915/ http://dx.doi.org/10.1192/j.eurpsy.2021.1136 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Abstract Regueira, P. Cerejeira, J. The use of methylphenidate in vascular dementia: A case report |
title | The use of methylphenidate in vascular dementia: A case report |
title_full | The use of methylphenidate in vascular dementia: A case report |
title_fullStr | The use of methylphenidate in vascular dementia: A case report |
title_full_unstemmed | The use of methylphenidate in vascular dementia: A case report |
title_short | The use of methylphenidate in vascular dementia: A case report |
title_sort | use of methylphenidate in vascular dementia: a case report |
topic | Abstract |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9475915/ http://dx.doi.org/10.1192/j.eurpsy.2021.1136 |
work_keys_str_mv | AT regueirap theuseofmethylphenidateinvasculardementiaacasereport AT cerejeiraj theuseofmethylphenidateinvasculardementiaacasereport AT regueirap useofmethylphenidateinvasculardementiaacasereport AT cerejeiraj useofmethylphenidateinvasculardementiaacasereport |